| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/129.SUPPLEMENT_1.S13 |
| P953 | full work available at URL | http://academic.oup.com/jid/article-pdf/129/Supplement_1/S13/2634222/129-Supplement_1-S13.pdf |
| P698 | PubMed publication ID | 4596516 |
| P2093 | author name string | D. C. Cavanaugh | |
| J. D. Marshall | |||
| K. F. Meyer | |||
| P. J. Bartelloni | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunization | Q1415366 |
| P304 | page(s) | Suppl:S13-8 | |
| P577 | publication date | 1974-05-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Plague immunization. I. Past and present trends | |
| Plague Immunization. I. Past and Present Trends | |||
| P478 | volume | 129 |
| Q92090453 | A Recombinant Attenuated Yersinia pseudotuberculosis Vaccine Delivering a Y. pestis YopENt138-LcrV Fusion Elicits Broad Protection against Plague and Yersiniosis in Mice |
| Q41462360 | A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice |
| Q33801151 | A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection |
| Q41446828 | A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. |
| Q36237899 | A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen |
| Q34778198 | A live attenuated strain of Yersinia pestis KIM as a vaccine against plague |
| Q41537094 | Antibody response to plague vaccination in humans as assayed by staphylococcal radioimmune precipitation (St-RIP) test |
| Q33698142 | Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines. |
| Q34045080 | Biosafety level 2 model of pneumonic plague and protection studies with F1 and Psa. |
| Q39393406 | Cell-mediated protection against pulmonary Yersinia pestis infection |
| Q35998760 | Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy |
| Q36628038 | Current challenges in the development of vaccines for pneumonic plague |
| Q41461622 | Defining the genome content of live plague vaccines by use of whole-genome DNA microarray |
| Q34128266 | Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. |
| Q37599376 | Developing live vaccines against plague. |
| Q34159659 | Establishment of a Swiss Webster mouse model of pneumonic plague to meet essential data elements under the animal rule |
| Q41434118 | Expression of an immunogenic F1-V fusion protein in lettuce as a plant-based vaccine against plague. |
| Q41453869 | Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection |
| Q34633478 | HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model |
| Q33788286 | Human immune response to a plague vaccine comprising recombinant F1 and V antigens |
| Q93357637 | Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine |
| Q33584403 | Immune defense against pneumonic plague |
| Q35385770 | Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague |
| Q36316792 | Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague. |
| Q35530270 | Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague |
| Q34343294 | Intranasal vaccination against plague, tetanus and diphtheria |
| Q35745842 | Intraspecific diversity of Yersinia pestis. |
| Q34819434 | Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge |
| Q35029718 | Model systems to study plague pathogenesis and develop new therapeutics |
| Q33824782 | Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost |
| Q36804222 | Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. |
| Q28066875 | Plague Vaccine Development: Current Research and Future Trends |
| Q38813137 | Plague Vaccines: Status and Future |
| Q62486778 | Plague vaccine: recent progress and prospects |
| Q41462618 | Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen |
| Q89878357 | Protection and Safety Evaluation of Live Constructions Derived from the Pgm- and pPCP1- Yersinia pestis Strain |
| Q39111815 | Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V) |
| Q33788149 | Protein microarray for profiling antibody responses to Yersinia pestis live vaccine |
| Q41475840 | Pulmonary Manifestations of Bioterrorism |
| Q41436628 | Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice |
| Q36373952 | Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection |
| Q35557573 | Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization |
| Q92644859 | Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague |
| Q64112896 | Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization |
| Q41451306 | Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection |
| Q37191268 | Yersinia pestis IS1541 transposition provides for escape from plague immunity |
| Q35091255 | Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague |
| Q36594087 | Yersinia pestis caf1 variants and the limits of plague vaccine protection |
| Q29619320 | Yersinia pestis--etiologic agent of plague |
Search more.